Cancer: A Ras and NF-κB pas de deux

Nature Reviews Drug Discovery

Volumn 8, Issue 12, 2009, Pages 932-933

  Chenette, Emily J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN P53; RAS PROTEIN;

ADENOCARCINOMA; ANIMAL; DRUG DELIVERY SYSTEM; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; MUTATION; NOTE; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG DELIVERY SYSTEMS; HUMANS; LUNG NEOPLASMS; MUTATION; NF-KAPPA B; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 73449108101     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3060     Document Type: Article

References (2)

1. Meylan, E. et al. Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma. Nature 462, 104-107 (2009)
2. Barbie, D. A. et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108-112 (2009)